PDB Entry - 5F4N
(Status - Released)Summary information:
Title: Multi-parameter lead optimization to give an oral CHK1 inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
PDB DOI: https://doi.org/10.2210/pdb5f4n/pdb
Primary publication DOI: https://doi.org/10.1021/acs.jmedchem.5b01938
Entry authors: Collins, I., Garrett, M.D., van Montfort, R., Osborne, J.D., Matthews, T.P., McHardy, T., Proisy, N., Cheung, K.J., Lainchbury, M., Brown, N., Walton, M.I., Eve, P.D., Boxall, K.J., Hayes, A., Henley, A.T., Valenti, M.R., De Haven Brandon, A.K., Box, G., Westwood, I.M., Jamin, Y., Robinson, S.P., Leonard, P., Reader, J.C., Aherne, G.W., Raynaud, F.I., Eccles, S.A.
Initial deposition on: 3 December 2015
Initial release on: 25 May 2016
Latest revision on: 22 June 2016
Downloads:
Structure coordinates (PDBx/mmCIF)
Structure coordinates (PDBML)
Structure coordinates (PDB)
X-ray diffraction data (PDBx/mmCIF)
Validation report (PDF)
Validation report (XML)
Links to more resources for 5F4N at: